CriticalClass Ia antiarrhythmic with antimuscarinic activity×Non-dihydropyridine calcium channel blocker
Updated · Methodology
Mechanism
Both drugs are antiarrhythmics: the US label classes disopyramide as class I (disopyramide label, US Food and Drug Administration, FDA), and the Spanish disopyramide summary of product characteristics (SmPC) lists verapamil as a class IV antiarrhythmic (disopyramide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Verapamil acts on the sinoatrial and atrioventricular (AV) nodes and prolongs AV conduction (verapamil SmPC, AEMPS). Disopyramide has negative inotropic properties (disopyramide SmPC, AEMPS) and can prolong the QT interval (FDA). Verapamil and other antiarrhythmics potentiate each other's cardiac effects (verapamil SmPC, AEMPS). Verapamil also inhibits CYP3A4, which metabolises disopyramide, so disopyramide levels may rise, but the documents give no figures for this pair (verapamil and disopyramide SmPCs, AEMPS).
Symptoms
With antiarrhythmics, verapamil can cause high-grade atrioventricular (AV) block, marked slowing of the heart rate, heart failure and a sharp fall in blood pressure (verapamil summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When intravenous verapamil was given with disopyramide to patients with severe cardiomyopathy, congestive heart failure or recent myocardial infarction, serious adverse effects occurred in rare cases (AEMPS). Disopyramide can cause or worsen heart failure and severe hypotension, prolong the QT interval and cause ventricular tachycardia, ventricular fibrillation and torsades de pointes (disopyramide label, US Food and Drug Administration, FDA). QT prolongation and QRS widening show only on an electrocardiogram (ECG).
Management
The combination is contraindicated. The disopyramide summary of product characteristics (SmPC) contraindicates other antiarrhythmics and, under contraindicated combinations, names verapamil as a class IV antiarrhythmic (disopyramide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The exceptions in the same SmPC are beta-blockers for angina and digoxin with beta-blockers and verapamil for rate control in atrial fibrillation. Disopyramide is not among them (AEMPS). When switching from one drug to the other, do not give disopyramide within 48 hours before or 24 hours after verapamil (verapamil and disopyramide labels, US Food and Drug Administration, FDA). During disopyramide treatment, monitor the QT interval and QRS duration and stop the drug if they lengthen by more than 25%. Monitor blood potassium and correct it if needed (disopyramide SmPC, AEMPS). Stop verapamil if second- or third-degree atrioventricular (AV) block or unifascicular, bifascicular or trifascicular bundle branch block develops (verapamil SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Disopiramida (nº registro 52549), sección 4.5 (2025)– AEMPS, CIMA, nº registro 52549 (Dicorynan), revisión 03/2025, secciones 4.3, 4.4 y 4.5
- FDA: Norpace (disopyramide) prescribing information (2026)– DailyMed setid e2aa1642-d262-4520-bc6a-9fd3ad795677, revisión 08/2026, Contraindications, Precautions – Drug Interactions
- FDA: Verapamil hydrochloride injection prescribing information (Hospira) (2026)– FDA label, DailyMed setid 1c993365-1b62-4524-e781-d307f28f63bc, revised 07/2026, Contraindications and PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Verapamilo (Manidon Retard 120 mg) (nº registro 53434), secciones 4.3, 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 53434, revisión 06/2024, secciones 4.3, 4.4 y 4.5